Beeline Medicines has emerged from stealth mode, backed by Bain Capital and Bristol Myers Squibb, to develop precision therapies for immune diseases. Their lead candidate is afimetoran, a promising oral treatment for systemic lupus erythematosus, currently in Phase 2 trials. Beeline also has drugs in early testing for atopic dermatitis, lupus, and plaque psoriasis, along with two preclinical assets targeting other proteins. The company has secured $300 million in Series A funding and is led by Saqib Islam, a seasoned industry executive. Bain Capital has a history of successfully launching biotech firms through strategic partnerships and funding.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.biopharmadive.com/news/bain-beeline-immune-drugs-bristol-myers/817538/
